Today: 20 March 2026
Subscribe
Browse Category

Pfizer News 5 December 2025 - 13 March 2026

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer shares closed down 1% at $26.60 Friday after GSK’s RSV vaccine won expanded FDA approval for at-risk adults 18 to 49, narrowing Pfizer’s lead in the RSV market. Positive trial data for Pfizer’s blood thinner Eliquis offset some pressure, but the stock finished near session lows amid broader market weakness and uncertainty over the company’s near-term growth outlook.
13 March 2026
···
Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer shares slipped 0.1% to $25.06 in thin holiday trading Monday, with the stock moving between $24.99 and $25.19. Investors focused on Pfizer’s 2026 outlook and pipeline moves, including a $150 million licensing deal with China’s YaoPharma for an experimental obesity drug. Broader U.S. markets declined as tech stocks retreated. Pfizer expects revenue growth to resume in 2029.
29 December 2025
···
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer shares closed Friday at $25.09, trading in a narrow range on light volume ahead of the New Year’s holiday. No new company press releases have appeared since Dec. 18. The stock remains below its 52-week high of $27.69, with dividend yield drawing investor focus as Wall Street weighs declining COVID revenues against future growth in oncology and obesity drugs.
27 December 2025
···
Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer shares closed at $25.03 on Dec. 24, ahead of Christmas, after the company issued 2026 guidance below Wall Street forecasts. The drugmaker projected 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and loss of exclusivity. Pfizer declared a $0.43 per share Q1 2026 dividend, its 349th consecutive payout.
25 December 2025
···
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer shares traded near $25.04 midday Friday after a volatile week, holding steady despite new policy headlines and a guidance reset. The company issued 2026 revenue guidance of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. Pfizer also reported positive Phase 3 results for PADCEV + Keytruda in bladder cancer.
19 December 2025
···
Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer shares traded at $25.04 on Dec. 18, 2025, down 1.8% after management issued cautious 2026 guidance with revenue forecast at $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00. The company cited lower COVID product sales and patent expirations as major headwinds. Pfizer stock has dropped over 50% since early 2023. Investors remain focused on its dividend yield and oncology developments.
18 December 2025
··
Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer shares closed down 1.9% at $25.04 Wednesday, hitting session lows despite positive Phase 3 results for PADCEV plus KEYTRUDA in bladder cancer. The stock edged up to $25.07 after hours. Investors weighed new 2026 guidance projecting $59.5–$62.5 billion in revenue and a $1.5 billion decline in COVID-19 product sales. Broader U.S. market weakness also pressured the stock.
18 December 2025
··
Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer shares traded near $25.50 Wednesday after the company issued 2026 revenue guidance of $59.5–$62.5 billion and forecast adjusted EPS of $2.80–$3.00, below Wall Street expectations. The company also cut its 2025 revenue outlook to about $62 billion. Shares fell about 5% after the update. Pfizer cited lower COVID product sales and ongoing patent losses as key headwinds.
17 December 2025
···
Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

Pfizer shares fell 3.4% to $25.53 late Dec. 16 after the company issued 2026 guidance projecting flat-to-declining revenue and adjusted EPS of $2.80–$3.00. The outlook cited lower COVID product sales and a $1.5 billion hit from patent expirations. Pfizer expects no share buybacks through 2026. Wall Street noted the EPS target is slightly below consensus.
17 December 2025
····
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer closed Friday at $25.85, near the upper end of its 52-week range. Investors are focused on the company’s analyst call Tuesday, where management will issue 2026 financial guidance. Pfizer’s dividend yield remains in the mid-6% range, while short interest stands at about 2.45% of float. Policy uncertainty for COVID vaccines and efforts to grow oncology and cardiometabolic revenue remain in focus.
14 December 2025
··
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer shares closed at $25.85 on Dec. 12, 2025, up 0.19%, and edged to $25.89 in after-hours trading. The company declared a $0.43 per-share dividend for Q1 2026. Trading volume reached 50.8 million shares during the session, with 1.56 million shares after hours. U.S. markets remain closed until Monday, Dec. 15.
13 December 2025
··
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer shares closed up 0.19% at $25.85 Friday, with after-hours trading lifting the stock slightly to $25.88. The company declared a $0.43 per-share quarterly dividend, payable March 6, 2026. Investors also reacted to reports of a possible FDA “black box” warning for COVID-19 vaccines and new late-stage data on breast-cancer drug Tukysa.
13 December 2025
··
Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer shares traded near $26 late December 5, up about 1%, with a market cap of $146 billion and a dividend yield close to 7%. New analyst coverage flagged tighter FDA COVID vaccine rules and looming patent expirations for key drugs as risks. The stock remains 36% below its five-year level despite recent gains. Investors await updated 2026 guidance and details on a major obesity-drug acquisition.
5 December 2025
···
1 2

Stock Market Today

  • Genuine Parts (GPC) Shares Decline Deepens, DCF Model Suggests Undervaluation
    March 20, 2026, 4:45 AM EDT. Genuine Parts (GPC) stock has fallen 7.4% last week and 21.2% over the past month, extending a year-to-date decline of 20.1%. The three-year loss nears 29.8%, with five-year returns down 2.7%. Despite these price drops, a Discounted Cash Flow (DCF) analysis estimates intrinsic value at $165.24 per share, about 40% above the current $99.09 market price, signaling potential undervaluation. The DCF model projects substantial free cash flow growth by 2035, supporting this view. Investors face a critical decision: whether recent price moves reflect Genuine Parts' fundamentals or market sentiment is overly pessimistic. Additional valuation metrics, including price-to-sales multiples, are considered for a holistic assessment.
Go toTop